Drug Profile
Research programme: anti-transforming growth factor beta antibodies - argenx
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator argenx
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in Netherlands (Parenteral)
- 16 Mar 2018 Early research in Cancer in Netherlands (Parenteral)